Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000338363 | SCV000334482 | uncertain significance | not provided | 2015-08-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001352545 | SCV001547106 | uncertain significance | Qualitative or quantitative defects of dysferlin | 2021-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine with valine at codon 1647 of the DYSF protein (p.Leu1647Val). The leucine residue is moderately conserved and there is a small physicochemical difference between leucine and valine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with DYSF-related conditions. ClinVar contains an entry for this variant (Variation ID: 282820). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001828189 | SCV002082355 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2020-08-18 | no assertion criteria provided | clinical testing |